These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15377171)

  • 1. Criteria for the design and biological characterization of radiolabeled peptide-based pharmaceuticals.
    Benedetti E; Morelli G; Accardo A; Mansi R; Tesauro D; Aloj L
    BioDrugs; 2004; 18(5):279-95. PubMed ID: 15377171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and preclinical evaluation of radiolabeled peptides for diagnosis and therapy.
    Aloj L; Morelli G
    Curr Pharm Des; 2004; 10(24):3009-31. PubMed ID: 15379665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Overview of Bioactive Peptides for in vivo Imaging and Therapy in Human Diseases.
    Tornesello AL; Tornesello ML; Buonaguro FM
    Mini Rev Med Chem; 2017; 17(9):758-770. PubMed ID: 28117023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomedical applications of radioiodinated peptides.
    Oliveira MC; Correia JDG
    Eur J Med Chem; 2019 Oct; 179():56-77. PubMed ID: 31238251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, radiolabeling and in vitro and in vivo characterization of tumor-antigen- and antibody-derived peptides for the detection of breast cancer.
    Okarvi SM; Jammaz IA
    Anticancer Res; 2009 Apr; 29(4):1399-409. PubMed ID: 19414394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and in vitro evaluation of heterobivalent peptidic radioligands targeting both GRP- and VPAC
    Lindner S; Fiedler L; Wängler B; Bartenstein P; Schirrmacher R; Wängler C
    Eur J Med Chem; 2018 Jul; 155():84-95. PubMed ID: 29864700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic applications of radiolabeled peptides in nuclear endocrinology.
    Behr TM; Béhé M; Becker W
    Q J Nucl Med; 1999 Sep; 43(3):268-80. PubMed ID: 10568142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candidates for peptide receptor radiotherapy today and in the future.
    Reubi JC; Mäcke HR; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():67S-75S. PubMed ID: 15653654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical in vivo cancer, straightway to patients?
    de Jong M; Mather S; Maina T
    Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):145-152. PubMed ID: 28347131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-targeting conjugates designed to improve the efficacy of radiolabeled peptides.
    Kluba CA; Bauman A; Valverde IE; Vomstein S; Mindt TL
    Org Biomol Chem; 2012 Oct; 10(37):7594-602. PubMed ID: 22898743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and exploration of novel radiolabeled bombesin peptides for targeting receptor positive tumor.
    De K; Banerjee I; Sinha S; Ganguly S
    Peptides; 2017 Mar; 89():17-34. PubMed ID: 28088445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of a
    Mikaeili A; Erfani M; Sabzevari O
    Nucl Med Biol; 2017 Nov; 54():10-17. PubMed ID: 28810154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of electrospray mass spectrometry for the characterization, design, and development of nitrido technetium and rhenium heterocomplexes as potential radiopharmaceuticals.
    Tisato F; Bolzati C; Porchia M; Refosco F
    Mass Spectrom Rev; 2004; 23(5):309-32. PubMed ID: 15264232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of a ligand targeting the somatostatin-2 receptor for drug delivery to neuroendocrine cancers.
    Li G; Low PS
    Bioorg Med Chem Lett; 2015 Apr; 25(8):1792-1798. PubMed ID: 25791453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationship study towards non-peptidic positron emission tomography (PET) radiotracer for gastrin releasing peptide receptors: Development of [
    Lacivita E; Lucente E; Kwizera C; Antunes IF; Niso M; De Giorgio P; Perrone R; Colabufo NA; Elsinga PH; Leopoldo M
    Bioorg Med Chem; 2017 Jan; 25(1):277-292. PubMed ID: 27863916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging.
    Gourni E; Mansi R; Jamous M; Waser B; Smerling C; Burian A; Buchegger F; Reubi JC; Maecke HR
    J Nucl Med; 2014 Oct; 55(10):1719-25. PubMed ID: 25146125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical dose number and its application in understanding drug absorption risk and formulation design for preclinical species.
    Wuelfing WP; Daublain P; Kesisoglou F; Templeton A; McGregor C
    Mol Pharm; 2015 Apr; 12(4):1031-9. PubMed ID: 25671350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiolabeled peptides in nuclear oncology: influence of peptide structure and labeling strategy on pharmacology.
    Maecke HR
    Ernst Schering Res Found Workshop; 2005; (49):43-72. PubMed ID: 15524210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving the stability of peptidic radiotracers by the introduction of artificial scaffolds: which structure element is most useful?
    Bacher L; Fischer G; Litau S; Schirrmacher R; Wängler B; Baller M; Wängler C
    J Labelled Comp Radiopharm; 2015 Aug; 58(10):395-402. PubMed ID: 26219022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.